21 completed, 3 terminated, 2 recruiting, 1 not yet recruiting. 10 Phase 2, 8 Phase 1, 4 Not applicable, 3 Phase 4, 2 Early Phase 1.
Follow Atovaquone: new trials by email Literature Review of Atovaquone trials Research Report on Atovaquone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives) Clindamycin + primaquine, Pentamidine, Atovaquone - Pneumocystis, Pneumocystis Infection | Phase 4 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 416 | 2026-03-01 | 2026-01-21 |
| Atovaquone Combined With Radiation in Children With Malignant Brain Tumors Atovaquone, Radiation Therapy - High-grade Glioma, Medulloblastoma | Phase 1 | Recruiting | Emory University | 18 | 2025-03-28 | 2026-08-03 |
| Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer Atovaquone, Biopsy, Computed Tomography - Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Recruiting | Emory University | 28 | 2023-11-09 | 2026-10-01 |
| Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC Atovaquone Oral Suspension, Standard of care chemotherapy, Standard of care radiotherapy - Locally Advanced Non-Small Cell Lung Cancer | Phase 1 | Completed | University of Oxford | 21 | 2020-12-07 | 2026-01-29 |
| Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers Atovaquone / Proguanil 250/100 mg, Tegoprazan 50 mg, Esomeprazole 40 mg - Gastroesophageal Reflux Disease | Phase 1 | Completed | Seoul National University Hospital | 19 | 2020-11-25 | 2021-09-27 |
| Atovaquone for Treatment of COVID-19 Experimental Group, Placebo Group - COVID-19 | Phase 2 | Completed | University of Texas Southwestern Medical Center | 60 | 2020-07-22 | 2021-12-14 |
| Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection Atovaquone/Azithromycin - Covid19 | Phase 2 | Terminated | HonorHealth Research Institute | 3 | 2020-04-20 | 2026-06-29 |
| Safety and Efficacy of NF135 CPS Immunization CPS-immunization, malaria challenge infection, P. falciparum NF135.C10, malaria challenge infection, P. falciparum NF54 - Malaria,Falciparum, Controlled Human Malaria Infection | Not applicable | Terminated | Radboud University Medical Center | 43 | 2019-04-01 | 2023-05-26 |
| Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) Atovaquone, Cytarabine, Daunorubicin - Acute Myeloid Leukemia | Early Phase 1 | Completed | Baylor College of Medicine | 26 | 2018-07-10 | 2026-06-23 |
| Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis atovaquone/proguanil 250mg/100mg (A/P), PfSPZ Challenge (NF54), NaCl 0,9% - Malaria | Phase 1 | Completed | University Hospital Tuebingen | 30 | 2016-11-28 | 2019-07-15 |
| Atovaquone as Tumour HypOxia Modifier Atovaquone - Carcinoma, Non-Small-Cell Lung | Early Phase 1 | Completed | University of Oxford | 46 | 2016-05-01 | 2019-09-04 |
| Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension Atovaquone/proguanil HCL, Atovaquone - Malaria | Phase 1 | Completed | GlaxoSmithKline | 30 | 2012-04-01 | 2017-03-22 |
| Antiretroviral Drug Interaction Study in Volunteers With HIV Atovaquone 750 mg twice daily, Atovaquone 1500 mg twice daily - HIV, PCP | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 36 | 2011-10-31 | 2018-07-05 |
| Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria Sevuparin sodium + atovaquone/proquanil, atovaquone/proquanil - Malaria, Falciparum | Phase 1 / Phase 2 | Terminated | Modus Therapeutics AB | 53 | 2011-09-01 | 2014-08-19 |
| Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria Malarone (atovaquone + proguanil combination), RIAMET (artemether + LUMEFANTRIN combination) - Malaria | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 317 | 2010-07-01 | 2015-12-09 |
| Weekly Dosing of Malarone ® for Prevention of Malaria Atovaquone Proguanil, Procedure - malaria challenge - Malaria | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 35 | 2009-09-01 | 2013-11-25 |
| Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP) Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics - Pneumocystis Carinii Pneumonia | Phase 4 | Withdrawn | George Washington University | 2008-02-01 | 2017-06-27 | |
| Safety and Efficacy Study of IV Artesunate to Treat Malaria Artesunate, Malarone - Malaria | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 30 | 2006-03-01 | 2019-10-01 |
| A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children Azithromycin, Atovaquone, Sulfamethoxazole-Trimethoprim - Bacterial Infections, Pneumonia, Pneumocystis Carinii | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 690 | 2021-11-04 | |
| A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia Atovaquone - Pneumonia, Pneumocystis Carinii, HIV Infections | Not applicable | Completed | Glaxo Wellcome | 2005-06-24 |
Showing 20 of 28. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (11) · HIV Infections (10) · Pneumonia, Pneumocystis (10) · Malaria (6) · AIDS-Related Complex (3) · AIDS-Related Opportunistic Infections (2) · COVID-19 (2) · Encephalitis (2) · Infections (2) · Malaria, Falciparum (2) · Pneumonia (2) · Toxoplasmosis (2) · Toxoplasmosis, Cerebral (2) · Bacterial Infections (1) · Carcinoma, Non-Small-Cell Lung (1)
Glaxo Wellcome (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Emory University (2) · U.S. Army Medical Research and Development Command (2) · University of Oxford (2) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · George Washington University (1) · GlaxoSmithKline (1) · HonorHealth Research Institute (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Modus Therapeutics AB (1) · National Institutes of Health Clinical Center (CC) (1) · Radboud University Medical Center (1) · Seoul National University Hospital (1)
United States (18) · Puerto Rico (3) · United Kingdom (3) · Canada (2) · France (2) · Netherlands (2) · Belgium (1) · Germany (1) · Japan (1) · Kenya (1) · South Korea (1) · Tanzania (1) · Thailand (1)
Afsoon Roberts, M.D. (1) · Alexandra Stevens, MD (1) · Amneris Luque, M.D. (1) · Anna Leitgeb, PhD (1) · Chirgwin K (1) · Dorenbaum A (1) · El-Sadr W (1) · Emily G McDonald, MD MSc (1) · Ezimamaka Ajufo, M.D. (1) · Geoff Higgins, MBChB, MRCP, FRCR (1) · Geoffrey Higgins (1) · Gregory Deye, MD (1) · Helen King, M.D. (1) · Hesham Sadek, M.D. (1)
PMID 22052893, PMID 26797214, PMID 29244851, PMID 32479781, PMID 33439382, PMID 34964932, PMID 34988242, PMID 36526815, PMID 36897544, PMID 37024868, PMID 38235979
P30CA138292 (1)